Philippe Pouletty, Carvolix

Key Takeaways

• Carvolix offers AI guidance for cardiologists
• Robot automates transcatheter aortic valve implantation
• Upcoming device targets rapid brain‑clot removal
• Founder previously built biotech Abivax
• Emphasis on French med‑tech independence

Pulse Analysis

Artificial intelligence is rapidly moving from data analytics to procedural assistance in cardiology, a field that performed over 500,000 transcatheter aortic valve implantations (TAVIs) worldwide in 2025. Clinicians face mounting pressure to improve outcomes while shortening hospital stays, and AI‑powered decision tools promise to personalize device selection and predict complications. Europe’s aging population and the growing prevalence of aortic stenosis create a sizable market, encouraging startups to bridge the gap between imaging, machine learning, and real‑time operative guidance.

Carvolix differentiates itself by pairing an AI decision‑support platform with a fully automated robotic arm that can navigate catheters and deploy heart valves under physician supervision. Early feasibility studies in France and Germany report procedural times reduced by up to 20 percent and a 15 percent drop in contrast‑agent usage, key metrics for cost‑containment. The firm is also developing a neuro‑intervention robot designed to mechanically retrieve clots in acute ischemic stroke, a market projected to exceed $5 billion by 2030. Regulatory pathways appear favorable, as the European Union’s Medical Device Regulation (MDR) encourages innovative, evidence‑based technologies that demonstrate clear patient benefit.

Beyond the clinical advantages, Carvolix embodies a broader strategic shift toward European med‑tech sovereignty. By retaining ownership and scaling domestically, the company aims to reduce reliance on U.S. acquisition cycles that often dilute R&D focus. French venture capital has already pledged €45 million (≈ $48 million) to support the next phase of trials and commercial rollout. If successful, Carvolix could set a template for AI‑robotic integration across other specialties, accelerating the continent’s transition to high‑precision, minimally invasive care.